|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 354.85 USD | -0.14% |
|
+5.71% | +5.06% |
| 01-13 | Baird Adjusts Cencora Price Target to $415 From $392, Maintains Outperform Rating | MT |
| 01-12 | Cencora, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:00 AM |
| Capitalization | 68.84B 59.35B 55.25B 51.43B 95.76B 6,246B 103B 635B 251B 2,979B 258B 253B 10,879B | P/E ratio 2026 * |
24.9x | P/E ratio 2027 * | 21.7x |
|---|---|---|---|---|---|
| Enterprise value | 70.03B 60.37B 56.2B 52.32B 97.41B 6,354B 105B 646B 255B 3,031B 263B 257B 11,067B | EV / Sales 2026 * |
0.21x | EV / Sales 2027 * | 0.19x |
| Free-Float |
35.16% | Yield 2026 * |
0.64% | Yield 2027 * | 0.67% |
Last Transcript: Cencora, Inc.
| 1 day | -0.14% | ||
| 1 week | +5.71% | ||
| Current month | +5.06% | ||
| 1 month | +3.84% | ||
| 3 months | +11.10% | ||
| 6 months | +19.15% | ||
| Current year | +5.06% |
| 1 week | 333.95 |  | 356.86 |
| 1 month | 329.1 | | 356.86 |
| Current year | 329.1 | | 356.86 |
| 1 year | 237.71 | | 377.54 |
| 3 years | 147.48 | | 377.54 |
| 5 years | 100.71 | | 377.54 |
| 10 years | 68.38 | | 377.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Mauch
CEO | Chief Executive Officer | 59 | 30/09/2024 |
James Cleary
DFI | Director of Finance/CFO | 63 | 08/11/2018 |
Pawan Verma
CTO | Chief Tech/Sci/R&D Officer | 50 | 03/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Lon Greenberg
BRD | Director/Board Member | 75 | 15/05/2013 |
Robert Mauch
BRD | Director/Board Member | 59 | 30/09/2024 |
D. Mark Durcan
CHM | Chairman | 64 | 30/09/2025 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.14% | +5.71% | +47.31% | +116.00% | 68.84B | |
| -1.43% | -3.30% | +6.89% | +7.27% | 212B | |
| -2.26% | -0.79% | +11.01% | +20.06% | 124B | |
| -0.60% | +2.15% | -12.35% | -19.05% | 59.01B | |
| -1.11% | +1.34% | +24.63% | +93.17% | 54.23B | |
| +3.30% | +8.88% | - | - | 36.72B | |
| +0.43% | +3.18% | -18.03% | -35.89% | 27.12B | |
| +0.15% | +4.61% | +27.84% | +32.98% | 26.37B | |
| +0.38% | -0.47% | +7.48% | -33.98% | 24.07B | |
| -1.70% | -2.85% | -25.28% | +24.44% | 20.55B | |
| Average | -0.30% | +1.85% | +7.72% | +22.78% | 65.27B | |
| Weighted average by Cap. | -0.88% | +0.40% | +10.71% | +25.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 341B 294B 273B 254B 474B 30,906B 510B 3,145B 1,240B 14,742B 1,277B 1,251B 53,830B | 363B 313B 291B 271B 505B 32,917B 543B 3,349B 1,321B 15,701B 1,360B 1,332B 57,332B |
| Net income | 2.39B 2.06B 1.92B 1.78B 3.32B 217B 3.58B 22.05B 8.7B 103B 8.96B 8.77B 378B | 3.12B 2.69B 2.51B 2.33B 4.35B 283B 4.68B 28.84B 11.37B 135B 11.72B 11.48B 494B |
| Net Debt | 1.19B 1.02B 954M 888M 1.65B 108B 1.78B 10.97B 4.33B 51.43B 4.46B 4.36B 188B | -1.1B -948M -883M -822M -1.53B -99.8B -1.65B -10.15B -4B -47.6B -4.12B -4.04B -174B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 354.85 $ | -0.14% | 1,399,469 |
| 15/01/26 | 355.35 $ | +1.55% | 1,084,750 |
| 14/01/26 | 349.93 $ | +1.17% | 759,963 |
| 13/01/26 | 345.88 $ | +1.09% | 1,163,056 |
| 12/01/26 | 342.16 $ | +1.93% | 1,013,173 |
Delayed Quote Nyse, January 16, 2026 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- COR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition